Sul, J., Blumenthal, G. M., Jiang, X., He, K., Keegan, P., & Pazdur, R. (2016). FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist.

Sul, Joohee, Gideon M. Blumenthal, Xiaoping Jiang, Kun He, Patricia Keegan, and Richard Pazdur. "FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1." Oncologist 2016.

Sul, Joohee, et al. "FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1." Oncologist 2016.